source
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…Endpoints · 16d ago↗ source
- Deals, deals, deals; Biohaven takes on Eli Lilly; and moreWelcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding their cards close to the ...Endpoints · 18d ago↗ source
- Apnimed files for IPO as FDA reviews its sleep apnea drugApnimed is finally going forward with an IPO attempt after years of flirting with the milestone. The Cambridge, MA-based biotech revealed its Nasdaq plans on Friday night, following a strong six ...